A gene-editing therapy, potentially a one-time treatment, has shown promising results in reducing high cholesterol levels. The therapy has been reported to safely lower levels of "bad" cholesterol, including LDL and PCSK9, as well as triglycerides. Results from an early study, including a first-in-human trial, indicate the treatment may be effective in cutting "bad" cholesterol for an extended period.